DDIT3 and diffuse large B-cell lymphoma: GERS displayed a prognostic value in germinal-center B-cell&ndash;like subgroup (GCB) and activated B cell&ndash;like (ABC) molecular subgroups of patients as well as in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or Rituximab-CHOP (R-CHOP) regimens.